Pinealon: Benefits, Dosage & FDA Status
Pinealon (EDR)
A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.
FDA Status
Not FDA-approved — Russian-origin research peptide
Typical Dose
5–10 mg daily for 10–20 days (subcutaneous, cycled)
Evidence Grade
CPrimarily preclinical or anecdotal
Half-Life
Minutes
Routes of Administration
subcutaneous, intranasal
First Synthesized
2000s
Clinics Indexed
9 providers have offered Pinealon in our tracked directory.
Mechanism of Action
EDR tripeptide reported to penetrate BBB, modulate gene expression, and reduce neuronal oxidative damage.
Key Reported Benefits
- ✓Cognitive function (preclinical)
- ✓Reduced oxidative damage
- ✓Sleep/circadian effects
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C indicates primarily preclinical or anecdotal.
Reported Side Effects
- •Generally well-tolerated
Contraindications
- ⚠Pregnancy
Commonly Stacked With
Regulatory & Safety Context
FDA status: Not FDA-approved — Russian-origin research peptide
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on Pinealon. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
Semax
BA synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
Selank
BA synthetic analog of tuftsin with anxiolytic and nootropic properties. Modulates GABA and serotonin systems to reduce anxiety without sedation.
Epitalon
C+A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.
MOTS-c
BA 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
SS-31
B+A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
5-Amino-1MQ
C+A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.